Clinical Trial Detail

NCT ID NCT02747797
Title Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements yes
Sponsors eresa Helsten, MD
Indications

Advanced Solid Tumor

Therapies

Lucitanib

Age Groups: adult

Additional content available in CKB BOOST